Seiichi Okabe

10PUBLICATIONS
1CO-AUTHORS
Haematological tumoursPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsMedical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Feb 16, 2026
Dual Proteasome and Histone Deacetylase Inhibition Overcomes Tyrosine Kinase Inhibitor Resistance in Breakpoint Cluster Region: Abelson 1-Driven Leukaemia Cell Lines.

Seiichi Okabe, Seiichiro Yoshizawa, Yuya Arai

|Sep 02, 2025
Combination of WEE1 Inhibitor and Vitamin K2 Enhances Therapeutic Efficacy in Chronic Myeloid Leukemia.

Seiichi Okabe, Yuya Arai, Akihiko Gotoh

|Jul 08, 2025
Targeting WEE1 and asciminib suppresses ABL-tyrosine kinase inhibitor-resistant chronic myeloid leukemia cells.

Seiichi Okabe, Mitsuru Moriyama, Akihiko Gotoh

|Jun 20, 2025
Therapeutic Potential of Venetoclax and Selinexor in Targeting Hypoxia-Induced Vulnerabilities in Multiple Myeloma.

Seiichi Okabe, Yuya Arai, Yuko Tanaka

|Feb 06, 2025
Correspondence to: "Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations", Curik N et al. Leukemia. 2024; 38: 1415-1418.

Seiichi Okabe, Yuya Arai, Akihiko Gotoh

|Dec 24, 2024
Targeting the insulin-like growth factor-1 receptor to overcome imatinib resistance in chronic myeloid leukemia.

Seiichi Okabe, Yuya Arai, Akihiko Gotoh

Pageof 2

Frequent Collaborators

1 joint publications

Akihiko Gotoh